For patients undergoing cardiopulmonary bypass, myocardial protection is a key for successful recovery and improved outcomes following cardiac surgery that requires cardiac arrest. Different solutions, components and modes of delivery have evolved over the last few decades to optimise myocardial protection. These include cold and warm and blood and crystalloid solution through antegrade, retrograde or combined cardioplegia delivery approach. However, each method has its own advantages and disadvantages, posing a challenge to establish a gold-standard cardioplegic solution with an optimised mode of delivery for enhanced myocardial protection during cardiac surgery. The aim of this review is to provide a brief history of the development of cardioplegia, explain the electrophysiological concepts behind myocardial protection in cardioplegia, analyse the current literature and summarise existing evidence that warrants the use of varying cardioplegic techniques. We provide a comprehensive and comparative overview of the effectiveness of each technique in achieving optimal cardioprotection and propose novel techniques for optimising myocardial protection in the future.
ChatrathRKaulTWalkerD.Myocardial protection during cardioplegia in open-heart surgery: a review. Can Anaesth Soc J1980; 27: 381–388.
2.
HausenloyDBoston-GriffithsEYellonD.Cardioprotection during cardiac surgery. Cardiovasc Res2012; 94: 253–265.
3.
MelroseDDreyerBBentallH, et al. Elective cardiac arrest. Lancet1955; 266: 21–23.
4.
HearseDJGarlickPBHumphreySM.Ischemic contracture of the myocardium: mechanisms and prevention. Am J Cardiol1977; 39: 986–993.
5.
HearseDJ.Cardioplegia. Postgrad Med J1983; 59: 11–24.
6.
ReidemeisterJCHebererGBretschneiderHJ.Induced cardiac arrest by sodium and calcium depletion and application of procaine. Int Surg1967; 47: 535–540.
7.
LolleyDMHewittRLDrapanasT.Retroperfusion of the heart with a solution of glucose, insulin, and potassium during anoxic arrest. J Thorac Cardiovasc Surg1974; 67: 364–370.
8.
YaoHHanXHanX.The cardioprotection of the insulin-mediated PI3K/Akt/mTOR signaling pathway. Am J Cardiovasc Drugs2014; 14: 433–442.
9.
LaDisaJFKrolikowskiJGPagelPS, et al. Cardioprotection by glucose-insulin-potassium: dependence on K ATP channel opening and blood glucose concentration before ischemia. Am J Physiol: Hear Circ Physiol2004; 287: H601–H607.
10.
BuckbergGD.Strategies and logic of cardioplegic delivery to prevent, avoid, and reverse ischemic and reperfusion damage. J Thorac Cardiovasc Surg1987; 93: 127–139.
11.
CalafioreAMTeodoriGMezzettiA, et al. Intermittent antegrade warm blood cardioplegia. Ann Thorac Surg1995; 59: 398–402.
12.
BarnerHB.Blood cardioplegia: a review and comparison with crystalloid cardioplegia. Ann Thorac Surg1991; 52: 1354–1367.
13.
BeckerHJohansenJVBuckbergGD.Critical importance of ensuring cardioplegic delivery with coronary stenoses. J Thorac Cardiovasc Surg1981; 81: 507–515.
14.
GundrySRKirshMM.A comparison of retrograde cardioplegia versus antegrade cardioplegia in the presence of coronary artery obstruction. Ann Thorac Surg1984; 38: 124–127.
15.
YauTMWeiselRDMickleDAG, et al. Alternative techniques of cardioplegia. Circulation1992; 86: II377–184.
16.
BuckbergGD.Antegrade/retrograde blood cardioplegia to ensure cardioplegic distribution: operative techniques and objectives. J Card Surg1989; 4: 216–238.
17.
IhnkenKMoritaKBuckbergGD, et al. Simultaneous arterial and coronary sinus cardioplegic perfusion: an experimental and clinical study. Thorac Cardiovasc Surg1994; 42: 141–147.
18.
ShiraiTRaoVWeiselRD, et al. Antegrade and retrograde cardioplegia: alternate or simultaneous?J Thorac Cardiovasc Surg1996; 112: 787–796.
19.
DearaniJAAxfordTCPatelMA, et al. Role of myocardial temperature measurement in monitoring the adequacy of myocardial protection during cardiac surgery. Ann Thorac Surg2001; 72: S2235–S2243; discussion S2243–S2244.
20.
LopesJBSantosCCMDJr.Coronary perfusion pressure during antegrade cardioplegia in on-pump CABG patients. Braz J Cardiovasc Surg2017; 32: 171–176.
21.
YoungJNChoyIO.Aortic root pressure monitoring during antegrade cardioplegia administration. Ann Thorac Surg1996; 62: 1213–1214.
22.
EkeCGundrySFukushimaN, et al. Is there a safe limit to coronary sinus pressure during retrograde cardioplegia?Am J Surg1997; 63: 417–420.
23.
ChambersDJFallouhHB.Cardioplegia and cardiac surgery: pharmacological arrest and cardioprotection during global ischemia and reperfusion. Pharmacol Ther2010; 127: 41–52.
24.
FeyKFolletteDLivesayJ, et al. Effects of membrane stabilization on the safety of hypothermic arrest after aortic cross-clamping. Circulation1977; 56: II143–II117.
25.
GoldsteinSMNelsonRLMcConnellDH, et al. Effects of conventional hypothermic ischemic arrest and pharmacological arrest on myocardial supply/demand balance during aortic cross-clamping. Ann Thorac Surg1977; 23: 520–528.
26.
EngelmanRMRousouJHVertreesRA, et al. Safety of prolonged ischemic arrest during hypothermic cardioplegia. J Thorac Cardiovasc Surg1980; 79: 705–712.
27.
HoyerAKieferPBorgerM.Cardioplegia and myocardial protection: time for a reassessment?J Thorac Dis2019; 11: E76–E78.
28.
MushiyakhYDangariaHQaviS, et al. Treatment and pathogenesis of acute hyperkalemia. J Community Hosp Intern Med Perspect2012; 1: 7372.
29.
KayPHMunschCM.Techniques in extracorporeal circulation. London: Arnold, 2004.
30.
MurphyECrossHSteenbergenC.Sodium regulation during ischemia versus reperfusion and its role in injury. Circ Res1999; 84: 1469–1470.
31.
AvkiranMGrossGKarmazynM, et al. Na+/H+ exchange in ischemia, reperfusion and preconditioning. Cardiovasc Res2001; 50: 162–166.
32.
McCullyJDLevitskyS.The mitochondrial K(ATP) channel and cardioprotection. Ann Thorac Surg2003; 75: 667–673.
33.
ToyodaYLevitskySMcCullyJD.Opening of mitochondrial ATP-sensitive potassium channels enhances cardioplegic protection. Ann Thorac Surg2001; 71: 1281–1288; discussion 1288–1289.
34.
WakiyamaHCowanDBToyodaY, et al. Selective opening of mitochondrial ATP-sensitive potassium channels during surgically induced myocardial ischemia decreases necrosis and apoptosis. Eur J Cardiothorac Surg2002; 21: 424–433.
35.
HolmuhamedovELJovanovićSDzejaPP, et al. Mitochondrial ATP-sensitive K+ channels modulate cardiac mitochondrial function. Am J Physiol1998; 275: H1567–H1576.
36.
HolmuhamedovELWangLTerzicA.ATP-sensitive K+ channel openers prevent Ca2+ overload in rat cardiac mitochondria. J Physiol1999; 19: 347–360.
37.
PainTYangXMCritzSD, et al. Opening of mitochondrial K(ATP) channels triggers the preconditioned state by generating free radicals. Circ Res2000; 87: 460–466.
38.
JinZXZhouJJXinM, et al. Postconditioning the human heart with adenosine in heart valve replacement surgery. Ann Thorac Surg2007; 83: 2066–2072.
39.
LiuRXingJMiaoN, et al. The myocardial protective effect of adenosine as an adjunct to intermittent blood cardioplegia during open heart surgery. Eur J Cardiothorac Surg2009; 36: 1018–1023.
40.
ShalabyARinneTJärvinenO, et al. The impact of adenosine fast induction of myocardial arrest during CABG on myocardial expression of apoptosis-regulating genes Bax and Bcl-2. Cardiol Res Pract2009; 2009: 658965.
41.
SinghSDasDSSpadaccioC, et al. An overview of different methods of myocardial protection currently employed peri-transplantation. Vessel Plus2017; 1: 213–229.
42.
ChambersDHearseD.Heart physiology and pathophysiology (eds SperelakisNKurachiYTerzicA, et al.). 4th ed.New York: Academic Press, 2000.
43.
BretschneiderHJHübnerGKnollD. Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. J Cardiovasc Surg1975; 16: 241–260.
44.
LeeKChangCChuangY, et al. Combined St. Thomas and histidine-tryptophan-ketoglutarat solutions for myocardial preservation in heart transplantation patients. Transplant Proc2012; 44: 886–889.
45.
PetrowskyHClavienPA.Transplantation of the Liver. 3rd ed.Amsterdam: Elsevier, 2015, pp. 582–599.
46.
HearseDJStewartDABraimbridgeMV. Cellular protection during myocardial ischemia: the development and characterization of a procedure for the induction of reversible ischemic arrest. Circulation1976; 54: 193–202.
47.
ChambersDHaireKMorleyN, et al. St Thomas’ Hospital cardioplegia: enhanced protection with exogenous creatine phosphate. Ann Thorac Surg1996; 61: 67–75.
48.
CayirMYukselA.The use of Del Nido cardioplegia for myocardial protection in isolated coronary artery bypass surgery. Heart Lung Circ2020; 29: 301–307.
49.
MatteGdel NidoP. History and use of del Nido cardioplegia solution at Boston Children’s Hospital. J Extra Corpor Technol2012; 44: 98–103.
50.
BuelSStrikerCO’BrienJE.Del Nido versusSt.Thomas cardioplegia solutions: a single-center retrospective analysis of post cross-clamp defibrillation rates. J Extra Corpor Technol2016; 48: 67–70.
51.
HabertheuerAKocherALauferG, et al. Cardioprotection: a review of current practice in global ischaemia and future translational perspective. Biomed Res Int2014; 2014: 325725.
52.
MauneyMKronI.The physiologic basis of warm cardioplegia. Ann Thorac Surg1995; 60: 819–823.
53.
FanYZhangAXiaoY, et al. Warm versus cold cardioplegia for heart surgery: a meta-analysis. Eur J Cardiothorac Surg2010; 37: 912–919.
54.
MartinTCraverJGottJ, et al. Prospective, randomized trial of retrograde warm blood cardioplegia: myocardial benefit and neurologic threat. Ann Thorac Surg1994; 57: 298–302; discussion 302–304.
55.
LichtensteinSVAbelJGSalernoTA.Warm heart surgery and results of operation for recent myocardial infarction. Ann Thorac Surg1991; 52: 455–458; discussion 458–460.
56.
BorgerMWeiKRDWWeiselRD, et al. Myocardial perfusion during warm antegrade and retrograde cardioplegia: a contrast echo study. Ann Thorac Surg1999; 68: 955–961.
57.
KuhnEChoiYPyunJ, et al. Endothelial injury associated with cold or warm blood cardioplegia during coronary artery bypass graft surgery. Biomed Res Int2015; 2015: 256905.
58.
GuruVOmuraJAlghamdiA, et al. Is blood superior to crystalloid cardioplegia? A meta-analysis of randomized clinical trials. Circulation2006; 114: 331–338.
59.
ZengJHeWQuZ, et al. Cold blood versus crystalloid cardioplegia for myocardial protection in adult cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth2014; 28: 674–681.
60.
GundrySRSequeiraACoughlinTR, et al. Postoperative conduction disturbances: a comparison of blood and crystalloid cardioplegia. Ann Thorac Surg1989; 47: 384–390.
61.
GündayMBingölH.Is crystalloid cardioplegia a strong predictor of intra-operative hemodilution?2014; 9: 23.
62.
MullenJCFremesSEWeiselRD, et al. Right ventricular function: a comparison between blood and crystalloid cardioplegia. Ann Thorac Surg1987; 43: 17–24.
63.
ChitwoodWRJrWixonCLNortonTO, et al. Complex valve operations: antegrade versus retrograde cardioplegia. Ann Thorac Surg1995; 60: 815–818.
64.
BhayanaJNKalmbachTBoothFVM, et al. Combined antegrade/retrograde cardioplegia for myocardial protection: a clinical trial. J Thorac Cardiovasc Surg1989; 98: 956–960.
65.
JasinskiM.Comparison of retrograde versus antegrade cold blood cardioplegia: randomized trial in elective coronary artery bypass patients. Eur J Cardiothorac Surg1997; 12: 620–626.
66.
QuintilioCVociPBilottaF, et al. Risk factors of incomplete distribution of cardioplegic solution during coronary artery grafting. J Thorac Cardiovasc Surg1995; 109: 439–447.
67.
MenaschéPKuralSFauchetM, et al. Retrograde coronary sinus perfusion: a safe alternative for ensuring cardioplegic delivery in aortic valve surgery. Ann Thorac Surg1982; 34: 647–658.
68.
RadmehrHSoleimaniATatariH, et al. Does combined antegrade-retrograde cardioplegia have any superiority over antegrade cardioplegia. Heart Lung Circ2008; 17: 475–477.
69.
MurrayCJenningsRReimerK.Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation1986; 74: 1124–1136.
70.
PrzyklenkKBauerBOvizeM, et al. Regional ischemic ‘preconditioning’ protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation1993; 87: 893–899.
71.
ThielmannMKottenbergEKleinbongardP, et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet2013; 382: 597–604.
72.
WalshSTangTKullarP, et al. Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials. Eur J Cardiothorac Surg2008; 34: 985–994.
73.
HausenloyDJCandilioLEvansR, et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med2015; 373: 1408–1417.
74.
AriyaratnamPCaleALoubaniM, et al. Intermittent cross-clamp fibrillation versus cardioplegic arrest during coronary surgery in 6,680 patients: a contemporary review of an historical technique. J Cardiothorac Vasc Anesth2019; 33: 3331–3339.
75.
AlexJAnsariJGuerreroR, et al. Comparison of the immediate post-operative outcome of two different myocardial protection strategies: antegrade-retrograde cold St Thomas blood cardioplegia versus intermittent cross-clamp fibrillation. Interact Cardiovasc Thorac Surg2003; 2: 584–588.
76.
Sodi-PallaresDTestelliMFishlederB, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution of the electrocardiographic signs of myocardial infarction. Am J Cardiol1962; 9: 166–188.
77.
HausenloyDYellonD.New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res2004; 61: 448–460.
78.
RaoVChristakisGTWeiselRD, et al. The insulin cardioplegia trial: myocardial protection for urgent coronary artery bypass grafting. J Thorac Cardiovasc Surg2002; 123: 928–935.
79.
EllenbergerCSologashviliTKreienbühlL, et al. Protection by glucose-insulin-potassium in moderate- to high-risk patients undergoing elective on-pump cardiac surgery: a randomized controlled trial. Anesth Analg2018; 126: 1133–1141.
80.
FanYZhangAXiaoY, et al. Glucose-insulin-potassium therapy in adult patients undergoing cardiac surgery: a meta-analysis. Eur J Cardiothorac Surg2011; 40: 192–199.
81.
FergusonZYarboroughDJarvisB, et al. Evidence-based medicine and myocardial protection: where is the evidence. Perfusion2015; 30: 415–422.
82.
AlbackerTBChaturvediRAl KindiAH, et al. The effect of using microplegia on perioperative morbidity and mortality in elderly patients undergoing cardiac surgery. Interact Cardiovasc Thorac Surg2009; 9: 56–60.
83.
OnoratiFSantiniFDandaleR, et al. ‘Polarizing’ microplegia improves cardiac cycle efficiency after CABG for unstable angina. Int J Cardiol2013; 167: 2739–2746.
84.
KatusHLooserSHallermayerK, et al. Development and in vitro characterization of a new immunoassay of cardiac troponin T. Clin Chem1992; 38: 386–393.
85.
OhmanEMArmstrongPWChristensonRH, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N Engl J Med1996; 335: 1333–1341.
86.
ThygesenKAlpertJSJaffeAS, et al. Fourth universal definition of myocardial infarction. Eur Heart J2019; 40: 237–269.
87.
GoharAChongJPCLiewOW, et al. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction. Eur J Heart Fail2017; 19: 1638–1647.
88.
MauermannEBolligerDFasslJ, et al. Association of troponin trends and cardiac morbidity and mortality after on-pump cardiac surgery. Ann Thorac Surg2017; 104: 1289–1297.
89.
DomanskiMJMahaffeyKHasselbladV, et al. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA2011; 305: 585–591.
90.
GoodmanSGStegPGEagleKA, et al. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). Am Heart J2006; 151: 654–660.
91.
KimMLorinskyMKGoldCA, et al. Usefulness of circulating caspase-3 p17 and caspase-1 p20 peptides and cardiac troponin 1 during cardioplegia to gauge myocardial preservation. Am J Cardiol2019; 123: 899–904.
92.
JenningsRBSommersHMSmythGA, et al. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol1960; 70: 68–78.
93.
CromptonMCostiAHayatL.Evidence for the presence of a reversible Ca2+-dependent pore activated by oxidative stress in heart mitochondria. Biochem J1987; 245: 915–918.
94.
GriffithsEHalestrapA.Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J1995; 307: 93–98.
95.
HausenloyDKunstGBoston-GriffithsE, et al. The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial. Heart2014; 100: 544–549.
96.
ChiariPAngoulvantDMewtonN, et al. Cyclosporine protects the heart during aortic valve surgery. Anesthesiology2014; 121: 232–238.
97.
CungTMorelOCaylaG, et al. Cyclosporine before PCI in patients with acute myocardial infarction. N Engl J Med2015; 373: 1021–1031.
98.
MalouitreSDubeHSelwoodD, et al. Mitochondrial targeting of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced cytoprotection after glucose and oxygen deprivation. Biochem J2010; 425: 137–148.
99.
JinQLiRHuN, et al. DUSP1 alleviates cardiac ischemia/reperfusion injury by suppressing the Mff-required mitochondrial fission and Bnip3-related mitophagy via the JNK pathways. Redox Biol2018; 14: 576–587.
